Results 111 to 120 of about 45,933 (222)
British Journal of Pharmacology, EarlyView.Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen +12 more
wiley +1 more source
Characteristics of everolimus therapy.
, 2018 Characteristics of everolimus therapy.
Maureen P. Neary (3588749) +5 more
core +1 more source
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan +15 more
wiley +1 more source
, 2017 Overwhelming evidence shows a primary role for the mammalian target of rapamycin (mTOR) signaling in the pathogenesis of Alzheimer's disease (AD).
Dolcetta Diego +4 more
core
Oral Surgery, EarlyView.ABSTRACT Background Osteonecrosis of the jaws is associated with various drugs, including antiresorptives such as bisphosphonates and denosumab, as well as antiangiogenics. These drugs are used for the treatment of multiple diseases, notably osteoporosis, bone metastases, Paget's disease, osteogenesis imperfecta, malignant hypocalcaemia, among others ...
Rodríguez Naranjo Julia Alexandra +3 more
wiley +1 more source
Everolimus dual effects of an area vasculosa angiogenesis and lymphangiogenesis
, 2013 Recently approved as treatment for astrocytoma, kidney and pancreatic cancer, everolimus acts on tumor cells by inhibiting tumor cell growth and proliferation, as well as by inhibition of angiogenic activity by both direct effects on vascular cell ...
Djonov, Valentin +6 more
core
EVEROLIMUS INDUCES MET INHIBITION BY INTEREFERING WITH FKBP12 DEPENDENT ACTIVATION” [PDF]
, 2017 Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin ...
Raimondo, Lucia
core +1 more source
Transplant Infectious Disease, EarlyView.Letermovir use for active R/R CMV infection was associated with treatment‐emergent resistance in approximately one‐third of patients, particularly in those with high baseline viral loads and delayed virological response. These findings support careful patient selection, close virological monitoring, and early resistance testing.
Tobias Veit +11 more
wiley +1 more source
Role of everolimus in the treatment of renal cell carcinoma
, 2009 Saby George1, Ronald M Bukowski21University of Texas Health Sciences Center, MC-8221, Division of Hematology and Oncology, San Antonio, Texas, USA; 2CCF Lerner College of Medicine Division of Hematology and Oncology, Cleveland, Ohio, USAAbstract: The ...
Saby George, Ronald M Bukowski
core
Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR) [PDF]
, 2015 The METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) was reported by Prof Choueiri at the European Cancer Congress 2015.
Toni Choueiri
core